Clinical Trial Update: MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas [Phase 2]

View source ↗

Summary

This clinical trial update summarizes the MALIBU Phase 2 study evaluating the combination of ibrutinib and rituximab in untreated marginal zone lymphoma. The tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma
• Nodal Marginal Zone Lymphoma
• Splenic Marginal Zone Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: International Extranodal Lymphoma Study Group (IELSG) | Conditions: Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING